和黄医药披露2026年上半年业绩，肿瘤产品销售增长但全年指引未上调

Oil slips in choppy trading amid Oman-Iran talks reports
Introduction & Market Context
HUTCHMED (HKEX:13, Nasdaq/AIM:HCM) presented its first-half 2026 results on July 30, showcasing accelerating commercial growth across its oncology portfolio while advancing a next-generation antibody-targeted therapy conjugate (ATTC) platform. The biotech company reported oncology revenue of $162 million, up 23% year-over-year, while maintaining profitability despite increased R&D investment in its expanding clinical pipeline.
The presentation comes as HUTCHMED’s stock trades at $172.50, down slightly from the prior close but positioned between its 52-week range of $153 to $273. The company’s balanced approach of commercial execution and innovation investment reflects its strategy to achieve self-sustainability while building long-term value through novel drug development.
Financial Performance Highlights
HUTCHMED delivered robust financial results in the first half of 2026, with total in-market sales reaching $280 million, representing 19% year-over-year growth. The performance was driven by strong demand across the company’s key oncology products, particularly in China and expanding international markets.
The following chart illustrates the company’s comprehensive achievements across commercial, pipeline, and innovation domains during the first half of 2026.
Consolidated oncology and immunology revenue reached $162 million in H1 2026, up 13% from the prior year period. Product revenue from the company’s four main oncology assets—ELUNATE, SULANDA, ORPATHYS, and FRUZAQLA—totaled $121 million, marking a 23% increase. This growth more than offset an expected decline in the low-margin "Other Ventures" distribution business, which fell 14% to $116 million.
The detailed financial breakdown shows varied performance across the portfolio, as presented in the company’s revenue tables.
Research and development expenses increased to $79 million from $72 million in the prior year period, reflecting investments in in-house discovery capabilities including talent acquisition and AI technology, as well as advancing multiple ATTC assets into global clinical trials. Despite higher R&D spending, HUTCHMED reported net income of $16 million, demonstrating continued profitability.
The company’s key financial metrics are illustrated in the following overview.
The year-over-year comparison requires important context: H1 2025 net income of $455 million included a one-time $416 million gain from the SHPL divestment and $21 million in share of SHPL profits before divestment. Excluding these non-recurring items, the underlying operating performance shows meaningful improvement.
HUTCHMED ended the period with approximately $1.4 billion in cash, providing substantial resources to fund ongoing clinical trials, new product launches, and business development activities. The company reiterated its full-year 2026 guidance for oncology and immunology consolidated revenue of $330 million to $450 million.
Commercial Delivery Excellence
HUTCHMED’s commercial portfolio demonstrated strong momentum across both established and expanding markets. FRUZAQLA, the company’s colorectal cancer treatment developed in partnership with Takeda, achieved in-market sales of $185 million in H1 2026, up 14% year-over-year on a constant exchange rate basis. Particularly noteworthy was the 70% growth in ex-U.S. markets, driven by geographical expansion and reimbursement progress.
The global expansion strategy for FRUZAQLA is detailed in the following market overview.
The drug has now launched in 41 markets worldwide, with recent entries including Portugal, Belgium, South Korea, and Mexico. New reimbursement was secured in France, and reimbursement is now available in approximately 50% of launched markets with strong uptake. Takeda reiterated its fiscal year guidance of 25% growth for FRUZAQLA. The company also highlighted approval of a third indication for renal cell carcinoma in May 2026, which should further expand the commercial opportunity.
In China, ELUNATE demonstrated robust growth with in-market sales of $61 million, up 41% year-over-year. The product successfully expanded its National Reimbursement Drug List coverage to second-line endometrial cancer, demonstrating a median progression-free survival of 9.5 months.
ELUNATE also received approval for second-line renal cell carcinoma in May 2026, showing a median progression-free survival of 22.2 months. The drug maintains a leading market share in third-line colorectal cancer in China, solidifying its commercial position in a competitive oncology landscape.
SULANDA posted equally impressive growth, with in-market sales of $18 million, up 45% year-over-year. The product benefited from a Chinese Society of Clinical Oncology guideline upgrade to the highest-level I recommendation, with updated guidance no longer recommending SSA dose escalation after progression. The company is executing a strategic pivot to focus on top-tier hospitals to maximize market penetration.
The performance and strategic positioning of ORPATHYS and SULANDA are shown in the following overview.
ORPATHYS (savolitinib) received approval for third-line MET-amplified gastric cancer in June 2026, with the company targeting inclusion of the SACHI study in the National Reimbursement Drug List by year-end. Together, ORPATHYS and SULANDA represent 12% of in-market sales, with management expressing a positive outlook despite competitive markets with new entrants.
Pipeline Progress & Innovation Platform
Beyond commercial execution, HUTCHMED highlighted significant pipeline advancement during the first half of 2026. The company achieved two regulatory approvals and has three New Drug Applications under review, while progressing its next-generation ATTC platform through clinical development.
Sovleplenib, a novel selective Syk inhibitor, represents a major near-term opportunity in hematology. The drug has NDAs under review in China for both immune thrombocytopenia (ITP) and warm antibody autoimmune hemolytic anemia (WAIHA), with potential approvals expected in the first half of 2027.
The market opportunity and strategic positioning for sovleplenib are illustrated below.
For ITP, the China market prevalence is estimated at approximately 360,000 patients by 2031, with sovleplenib offering predictable long-term stable disease control. For WAIHA, with an estimated China prevalence of 47,000 patients by 2031, sovleplenib would represent the first new targeted therapy in 30 years, addressing a significant unmet medical need.
Clinical data presented at the European Hematology Association 2026 conference demonstrated high durable response rates and good safety profiles for sovleplenib in both indications.
In the ESLIM-02 study for WAIHA, sovleplenib achieved a 66% durable response rate compared to 15% for placebo, with substantial reduction in rescue therapy (16% vs 54%). The time to response was notably faster at 3.1 weeks versus 6.3 weeks for placebo. In the ESLIM-01 study for ITP, sovleplenib demonstrated a 48.4% durable response rate in the double-blind phase compared to 0% for placebo, significantly outperforming other approved treatments including fostamatinib, efgartigimod, and rilzabrutinib.
The company’s comprehensive pipeline achievements during H1 2026 are summarized in the following overview.
Savolitinib, developed in collaboration with AstraZeneca, represents HUTCHMED’s second potential global commercial asset. The drug has two pivotal Phase III trials with data readouts expected in H2 2026. The global SAFFRON study enrolled 338 patients evaluating savolitinib in combination with TAGRISSO versus platinum-based doublet chemotherapy in second-line MET amplification/overexpression EGFR-mutant NSCLC. The China SANOVO study enrolled 412 patients comparing the combination with TAGRISSO versus TAGRISSO alone in first-line MET overexpression EGFR-mutant NSCLC.
The approved SACHI study in China demonstrated impressive efficacy, with median progression-free survival of 6.9 months versus 3.0 months for chemotherapy (HR: 0.32) in patients who received prior third-generation EGFR inhibitors. Median overall survival in the intention-to-treat population excluding patients who received subsequent MET inhibitors was 22.9 months versus 7.9 months (HR: 0.32).
HUTCHMED’s next-generation innovation centers on its ATTC platform, which conjugates potent PI3K/PIKK inhibitors to targeted antibodies. Two first-in-class assets have entered Phase I clinical trials: HMPL-A251 targeting HER2-expressing cancers and HMPL-A580 targeting EGFR-expressing tumors.
The HMPL-A251 program overview and market opportunity are detailed below.
HMPL-A251 targets the HER2-expressing breast cancer and HER2-positive solid tumor markets, competing in a space where Enhertu generated $5 billion in 2025 revenue with peak sales forecasts of $16 billion. Preclinical data demonstrated the compound’s potential to overcome resistance to Enhertu (DXd), showing significantly better inhibition of DXd-resistant cells at lower nanomolar concentrations. The global Phase I study is ongoing in HER2-positive or HER2-low patients.
The company’s AI-aided drug discovery platform and pipeline roadmap extend through 2029 and beyond.
HUTCHMED plans to initiate global clinical studies for HMPL-A830 (ATTC 3) in H2 2026, with two additional candidates expected to enter the clinic in 2027. The AI-aided platform aims to deliver multiple innovations annually, with multiple early-stage assets entering preclinical studies in 2028.
Strategic Outlook & Guidance
HUTCHMED articulated a clear strategic vision centered on three pillars: accelerating innovation, achieving near-term commercial progress, and pursuing business development opportunities. Acting CEO and CFO Johnny Cheng emphasized the company’s commitment to maintaining profitability while investing in growth, stating it is "a strong requirement by our board that we will continue to be breakeven."
The company’s forward-looking priorities are outlined in the following strategic framework.
On the innovation front, HUTCHMED is accelerating its ATTC platform with multiple assets entering the clinic and focusing on AI transformation to enhance drug discovery capabilities. For near-term commercial progress, management expects FRUZAQLA to reach its next sales milestone while preparing its hematology portfolio for commercial launch following anticipated sovleplenib approvals in H1 2027.
Business development remains an active priority, with the company engaging multiple multinational corporations in ATTC partnership discussions. While talks are still early stage, management indicated it will announce deals when they become material and disclosable, potentially providing upfront payments and validation of the platform’s value.
Key upcoming catalysts include two savolitinib Phase III readouts in H2 2026 (SAFFRON and SANOVO), sovleplenib approvals expected in H1 2027, ATTC clinical data anticipated in 2027, and five ATTC programs expected in the clinic by around mid-2027. The company projects having multiple early-stage ATTC assets entering preclinical studies by 2028.
HUTCHMED reiterated its full-year 2026 oncology and immunology revenue guidance of $330 million to $450 million, expressing confidence in exceeding the lower end even without business development contributions. Management highlighted that potential upside drivers include FRUZAQLA’s continued geographic expansion, possible ATTC partnering deals, and sustained momentum in China product sales.
Dr. Guangxiu Dai, head of discovery and global portfolio management, emphasized the strategic focus on next-generation innovation: "Our next wave of innovation focuses on ATTCs. We have two first-in-class assets which have entered the phase I clinical trials." This positioning reflects HUTCHMED’s evolution from a China-focused oncology company to a global innovator with a differentiated technology platform addressing large unmet medical needs in solid tumors.
The company’s path to self-sustainability appears increasingly credible, supported by strong commercial execution, a robust cash position, and a pipeline that balances near-term revenue opportunities with longer-term transformational potential through its ATTC platform.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.